AGM FY20 Presentation
Filed with ASX · · 14 pages · English
Expansion: Actively seeking new deal flow for technologies with a focus on oncology and the central nervous system ▪ Unique Platform Technology – OroMist™: Reformulate existing billion-dollar drugs for oral delivery, faster path to market, which can create cost and time savings ▪ TGA Approval Secured for ZolpiMist: ZolpiMist received TGA approval July 2020 for the treatment of short-term insomnia
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- R & D Tax Incentive refund received
- Investor Presentation November 2020
- Anagrelide Cancer Patent For Australia
- Appendix 4C - quarterly
- TGA Approval Granted For ZolpiMist
Later from Arovella Therapeutics
- AGM FY20 Chairmans address and virtual meeting guide
- Placement Offer to raise $2.76m
- Ordesa Feasibility Study Update
- Prospectus - Placement
- Company Update - Letter to Shareholders
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics